Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies
Roberts, Scott W., Elvang, Tara Laura Brandt, Syed, Laila, Samuelsen, Marianne Bork, Arp-Hansen, Eva Lisby, Nielsen, Henrik Kim, Lund, Ida Katrine, Dünweber, Dorte Lunøe, Listov-Saabye, Nicolai, Bjørn-Larsen, Dorte, Hjelmsmark, Anette, Mikkelsen, Tue Anker
Published in Therapeutic innovation & regulatory science (01.03.2023)
Published in Therapeutic innovation & regulatory science (01.03.2023)
Get full text
Journal Article
Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies
Roberts, Scott W., Elvang, Tara Laura Brandt, Syed, Laila, Samuelsen, Marianne Bork, Arp-Hansen, Eva Lisby, Nielsen, Henrik Kim, Lund, Ida Katrine, Dünweber, Dorte Lunøe, Listov-Saabye, Nicolai, Bjørn-Larsen, Dorte, Hjelmsmark, Anette, Mikkelsen, Tue Anker
Published in Therapeutic innovation & regulatory science (01.03.2023)
Published in Therapeutic innovation & regulatory science (01.03.2023)
Get full text
Journal Article